Correlated Drug Terms (1)

---

	Name (Synonyms)	Correlation
drug1822	Placebo Wiki	0.06

Correlated MeSH Terms (1)

---

	Name (Synonyms)	Correlation
D007239	Infection NIH	0.06

Correlated HPO Terms (0)

---

	Name (Synonyms)	Correlation

Primary Outcomes

Description: % positive serology at the end of the study or positive PCR test in the course of routine clinical practice

Measure: Documented cumulative incidence of SARS-CoV-2 infection

Time: Up to 4 months

---

Secondary Outcomes

Description: Number of days of documented sick leave for SARS-CoV-2

Measure: Sick leave for SARS-CoV-2

Time: Up to 4 months

---

Description: The number of days off work due to the quarantine imposed as a consequence to have acute respiratory symptoms, fever or infection documented by SARS-CoV-2

Measure: Days off work due to the quarantine

Time: Up to 4 months

---

Description: Number of days of quarantine imposed by close contact outside the center with SARS-CoV-2 positive

Measure: Quarantine imposed by close contact outside the center with SARS-CoV-2 positive

Time: Up to 4 months

---

Description: Number of MD, nursing, personnel management and services, etc.

Measure: Professional category

Time: Up to 4 months

---

Description: Number of days of self-reported fever (≥38 ºC)

Measure: Fever

Time: Up to 4 months

---

Description: Cumulative incidence of self-reported acute respiratory symptoms

Measure: Incidence of self-reported acute respiratory symptoms

Time: Up to 4 months

---

Description: Number of days of self-reported acute respiratory symptoms

Measure: Days of self-reported acute respiratory symptoms

Time: Up to 4 months

---

Description: Number of participants with pneumonia confirmed by X-ray

Measure: Incidence of pneumonia

Time: Up to 4 months

---

Description: Cumulative incidence of death from documented SARS-CoV-2 infection

Measure: Incidence of death from SARS-CoV-2 infection

Time: Up to 4 months

---

Description: Cumulative incidence of admissions to intensive care unit for documented SARS-CoV-2 infection

Measure: Incidence of admissions to Intensive Care Unit (ICU)

Time: Up to 4 months

---

Description: Number of days admitted to the ICU for documented SARS-CoV-2 infection

Measure: Days in ICU

Time: Up to 4 months

---

Description: Cumulative incidence of need for mechanical ventilation due to documented SARS-CoV-2 infection

Measure: Incidence of mechanical ventilation

Time: Up to 4 months

---

Description: Cumulative incidence of hospital admissions for documented SARS-CoV-2 infection

Measure: Incidence of hospital admissions

Time: Up to 4 months

---

Description: Number of days of hospitalization for documented SARS-CoV-2 infection

Measure: Days of hospitalization

Time: Up to 4 months

---

Description: Incidence of SARS-CoV-2 antibodies at the end of the study period

Measure: Incidence of SARS-CoV-2 antibodies

Time: Final visit

---

Description: Frequency and levels of immunoglobulin IgG and immunoglobulin IgM

Measure: Types of antibodies detected

Time: Final visit

---

Description: Levels of SARS-CoV-2 antibodies at the end of the study period

Measure: Levels of SARS-CoV-2 antibodies

Time: Final visit

---

Other Outcomes

Description: All adverse events reported by the subjects, both serious and non-serious, will be collected. All events related to a SARS-CoV-2 infection will be exempted from collection as part of the associated symptoms.

Measure: AEs

Time: Up to 4 months

---

Description: All those Adverse Events that lead to hospitalization of the patient, that endanger his life or cause or may cause death.

Measure: SAEs

Time: Up to 4 months

---